LILRB2 and nonpapillary renal cell carcinoma: The difference in survival outcomes between the two groups expressing Mono_CD16 signature markers was not significant in the UC and ccRCC cohorts (considering LILRB2 as one of the signature markers for Mono_CD16), however, when considering the additional expression of HLA-A and/or LILRA1, the higher-expression group demonstrated significantly lower survival rates in both cohorts (Supplementary Fig. 10).